Educational, research-use-only content. This article summarizes published scientific literature for informational purposes only and is not medical advice. The compounds discussed are supplied strictly for in-vitro laboratory research and are not approved for human or veterinary use.
What is CJC-1295?
CJC-1295 is a synthetic, long-acting analog of growth-hormone-releasing hormone (GHRH). It is studied in two forms: a shorter version and a “with DAC” (drug affinity complex) version engineered to bind albumin and dramatically extend its half-life (Teichman et al., 2005).
What the human research examined
In randomized, placebo-controlled trials in healthy adults, a single subcutaneous injection of CJC-1295 produced dose-dependent increases in growth hormone (roughly 2- to 10-fold) lasting six days or more, and increases in IGF-1 (about 1.5- to 3-fold) for 9–11 days. Its estimated half-life was about 6–8 days, with a cumulative effect after repeat dosing and no serious adverse reactions reported in the study (Teichman et al., 2005).
How it is thought to work
Like the body’s own GHRH, CJC-1295 stimulates the pituitary to release growth hormone — but its long half-life sustains that signal far longer than native GHRH, which acts only briefly.
The limits of the current evidence
- Human data are early-phase and focused on hormone levels, not long-term outcomes or safety.
- CJC-1295 is not an approved medicine, growth-hormone-axis stimulation requires medical oversight, and GHRH analogs are prohibited in sport by WADA.
References
According to PubMed:
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog, in healthy adults. J Clin Endocrinol Metab. 2005. doi:10.1210/jc.2005-1536
